Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan

RIGL•2026-08-04

Rigel outlined an exclusive global license with Arvinas and Pfizer for VEPPANU (vepdegestrant) in 2L+ ER+/HER2-, ESR1-mutated metastatic breast cancer.
VEPPANU launch set for mid-August; positioned as the first FDA-approved oral PROTAC.
2026 net product sales guidance shown at USD 260 million; portfolio sales rose 14% year over year to USD 47.4 million in Q2 2026.
Q2 net product sales split: TAVALISSE USD 27% higher year over year; GAVRETO USD 10.7 million; REZLIDHIA USD 8.9 million.
Cash balance ended 2025 at USD 155 million; strategy targets commercial expansion, pipeline advancement, financial discipline, in-licensing, M&A.

Sources

Docs